340B Drug Pricing Program
The AHA again expressed concern to the Department of Health and Human Services about recent actions taken by several major drug manufacturers to limit the distribution of certain 340B drugs to hospitals.
AHA to HHS again expressing concern with recent actions taken by several major drug manufacturers to limit the distribution of certain 340B drugs to our hospital members.
Statement on the FY 2021 final IPPS rule from AHA Senior Vice President for Public Policy Analysis and Development Ashley Thompson.
The AHA and other national health care groups urged the Department of Health and Human Services to protect 340B hospitals and the vulnerable communities they serve “from actions taken by five of the nation’s largest pharmaceutical manufacturers that undermine access to critical drugs and other…
On behalf of the nation’s 340B hospitals, AHA, others urge HHS to protect vulnerable communities from actions taken by five of the nation’s largest pharmaceutical manufacturers that undermine access to critical drugs and other health care services.
The AHA sent letters to the heads of U.S. operations for five large drug companies — Merck, Eli Lilly, Sanofi, Novartis and AstraZeneca — expressing “profound concern” over actions they are taking to limit the distribution of certain 340B drugs to hospitals and health systems and asking them to “…
For more than 25 years, the 340B program has enabled hospitals that care for many low-income and uninsured patients to purchase certain outpatient drugs from drug companies at discounted prices
AHA to Eli Lilly and Company Re: Actions to Collect Data to Limit Distribution of Certain 340B Drugs
AHA expresses profound concern about actions Eli Lilly and Company is taking to collect data intended to limit the distribution of certain 340B drugs to hospitals and health systems.
AHA expresses profound concern about actions AztraZeneca is taking to collect data intended to limit the distribution of certain 340B drugs to hospitals and health systems.
AHA expresses profound concern about actions Novartis Corporation Global, is taking to collect data intended to limit the distribution of certain 340B drugs to hospitals and health systems.